

Express Mail Label No. EL862126246US
Date of Deposition: August 30, 2001



PATENT APPLICATION
Attorney Docket No.: 15966-534C CIP1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

SEP 05 2001

APPLICANTS : Shimkets, et al
ASSIGNEE : CURAGEN CORPORATION
SERIAL NUMBER : 09/472,688
FILING DATE : December 27, 1999
FOR : NUCLEIC ACIDS CONTAINING SINGLE NUCLEOTIDE POLYMORPHISMS AND METHODS OF USE THEREOF

EXAMINER : M. Moran

ART UNIT : 1631

TECH CENTER 1600/2900

BOX SEQUENCE LISTING

August 30, 2001

Assistant Commissioner for Patents
Washington, D.C. 20231


TRANSMITTAL LETTER

Enclosed herewith are the following for the above-identified non-provisional patent application:


- ☒ Response to Notice to Comply with Sequence Listing Requirement Under 37 CFR §§ 1.821 – 1.825 (1 page);
- ☒ Copy of Notice to Comply with Sequence Listing Requirements (1 page);
- ☒ Substitute Computer Readable Form Copy of the "Sequence Listing" (1 diskette);
- ☒ Substitute Paper Copy of the "Sequence Listing" (237 pages);
- ☒ Statement in Support of Computer Readable Form Submission
Under 37 C.F.R. § 1.821(f) (1 page); and,
- ☒ Return postcard.

The Commissioner is hereby authorized to charge any fee that may be due, or to credit any overpayment, to Deposit Account No. 50-0311 (Reference No. 15966-534C CIP1 (Cura 34C CIP1)). A duplicate copy of this transmittal letter is enclosed.

Respectfully submitted,


Ivor R. Elrifi, Reg. No. 39,529
Naomi S. Biswas, Reg. No. 38,384
Attorneys for Applicants
c/o MINTZ, LEVIN
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

Express Mail Label No.: EL862126246US
Date of Deposit: August 30, 2001



#12
DIA
9/5/01

PATENT APPLICATION

Attorney Docket No. 15966-534C CIP1 (CURA-34C CIP1)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

SEP 05 2001

APPLICANTS : Shimkets et al.
ASSIGNEE : CuraGen Corporation
SERIAL NUMBER : 09/472,688
FILING DATE : December 27, 1999
FOR : NUCLEIC ACIDS CONTAINING SINGLE NUCLEOTIDE POLYMORPHISMS AND METHODS OF USE THEREOF

EXAMINER : M. Moran

ART UNIT : 1631

TECH CENTER 1600/2900

Commissioner for Patents and Trademarks
Washington, D.C. 20231

August 30, 2001
Boston, Massachusetts

**RESPONSE TO NOTICE TO COMPLY WITH SEQUENCE LISTING
REQUIREMENT UNDER 37 CFR §§ 1.821 - 1.825**

In response to the Notice to Comply with Sequence Listing Requirements, mailed July 30, 2001, Applicants submit a paper copy of the sequence listing, a computer readable form (CRF) copy of the sequence listing and a statement in support of the computer readable format, in compliance with 37 C.F.R. §§ 1.821-1.825.

This response is due on or before August 30, 2001. Applicants believe that no additional fees are due in this filing, however, the Commissioner is hereby authorized to charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311 (Attorney Reference No. 15966-534C CIP1, CURA-34C CIP1).

Should any questions or issues arise concerning this application, the Examiner is encouraged to contact the undersigned at the telephone number provided below.

Respectfully submitted,

Naomi S. Biswas

Ivor R. Elrifi, Reg. No. 39,529
Naomi S. Biswas, Reg. No. 38,384
Attorneys for Applicants
c/o MINTZ, LEVIN
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

Application No.: 09/472,688

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):



- ☐ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☒ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: _____

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☐ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE

Express Mail Label No.: EL862126246US
Date of Deposit: August 30, 2001



PATENT APPLICATION
Attorney Docket No. 15966-534C CIP1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

SEP 05 2001

TECH CENTER 1600/2900

APPLICANTS: Shimkets et al.

SERIAL NUMBER: 09/472,688

EXAMINER: M. Moran

FILING DATE: December 27, 1999

ART UNIT: 1631

FOR: Nucleic Acids Containing Single Nucleotide Polymorphisms and Methods of Use Thereof

August 30, 2001

BOX SEQUENCE LISTING

Commissioner for Patents and Trademarks
Washington, D.C. 20231

STATEMENT IN SUPPORT OF COMPUTER READABLE
FORM SUBMISSION UNDER 37 C.F.R. § 1.821(f)

I hereby state that the content of the paper and computer readable forms of the Sequence Listing, submitted in the above-identified application in accordance with 37 C.F.R. § 1.821(c) and 1.821(e), respectively, are the same. No new matter has been added.

Respectfully submitted,

Matthew Pavao
c/o Mintz, Levin
One Financial Center
Boston, MA 02111
Telephone (617) 542 6000
Fax: (617) 542 2241